Log in to save to my catalogue

Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable res...

Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable res...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_plos_journals_2392432682

Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma

About this item

Full title

Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma

Publisher

United States: Public Library of Science

Journal title

PloS one, 2020-04, Vol.15 (4), p.e0231828-e0231828

Language

English

Formats

Publication information

Publisher

United States: Public Library of Science

More information

Scope and Contents

Contents

Lenvatinib is an approved first-line therapy for unresectable hepatocellular carcinoma (HCC), but the effect of dose modification on its efficacy is unclear. We analyzed the relationship between the relative dose intensity during the initial 4 weeks of therapy [4W-relative dose intensity (RDI)] and the efficacy of lenvatinib therapy in the real-wor...

Alternative Titles

Full title

Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_plos_journals_2392432682

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_plos_journals_2392432682

Other Identifiers

ISSN

1932-6203

E-ISSN

1932-6203

DOI

10.1371/journal.pone.0231828

How to access this item